Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
評估ionis pharmaceuticals：來自6名金融分析師的見解。
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.
最近三個月，有6位分析師對Ionis Pharmaceuticals(NASDAQ:IONS)進行了評估，表達了看好和看淡的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他們最近的評級，展示了過去30天內的情緒演變並與之前的幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $65.0, a high estimate of $82.00, and a low estimate of $53.00. A 0.61% drop is evident in the current average compared to the previous average price target of $65.40.
分析師分析的12個月價格目標提供了洞察力，平均目標爲65.0美元，最高估值爲82.00美元，最低估值爲53.00美元。當前平均估值相比之前平均估值65.40美元下降了0.61%。
Breaking Down Analyst Ratings: A Detailed Examination
分析師評級分析：詳細分析
The analysis of recent analyst actions...
最近的分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。